Yaacov, A., Grinshpun, A., Gilis, R., Basheer, R., Peled, N. (2026). APOBEC mutational signatures to predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3130